GBM
MCID: GLB015
MIFTS: 75

Glioblastoma Multiforme (GBM)

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Glioblastoma Multiforme

MalaCards integrated aliases for Glioblastoma Multiforme:

Name: Glioblastoma Multiforme 12 74 52 58 54 6 15 17 71
Glioblastoma 52 58 29 54 6 43 71
Gbm 12 58
Grade Iv Adult Astrocytic Tumor 12
Primary Glioblastoma Multiforme 12
Adult Glioblastoma Multiforme 12
Spongioblastoma Multiforme 12
Primary Glioblastoma 71
Adult Glioblastoma 71

Characteristics:

Orphanet epidemiological data:

58
glioblastoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3068
MeSH 43 D005909
SNOMED-CT 67 63634009
MESH via Orphanet 44 D005909
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0017636 C1621958
Orphanet 58 ORPHA360
UMLS 71 C0017636 C0278878 C1514422 more

Summaries for Glioblastoma Multiforme

NIH Rare Diseases : 52 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1 , Turcot syndrome and Li Fraumeni syndrome . There is currently no cure for glioblastoma. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy .

MalaCards based summary : Glioblastoma Multiforme, also known as glioblastoma, is related to glioma susceptibility 1 and giant cell glioblastoma, and has symptoms including seizures and headache. An important gene associated with Glioblastoma Multiforme is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are TGF-Beta Pathway and Class I MHC mediated antigen processing and presentation. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are seizures and muscle weakness

Disease Ontology : 12 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

Wikipedia : 74 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Related Diseases for Glioblastoma Multiforme

Diseases related to Glioblastoma Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 1064, show less)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 34.8 TP53 PTEN PMS2 PIK3CA NRAS MTOR
2 giant cell glioblastoma 34.5 TP53 PTEN IDH1 FGFR1 EGFR BRAF
3 glial tumor 34.3 PTEN IDH1
4 glioma 34.3 TP53 PTEN PIK3CA MIR221 MIR210 MIR21
5 mismatch repair cancer syndrome 33.8 PTEN PMS2 MSH2
6 brain cancer 33.1 TP53 PTEN PMS2 PIK3CA NRAS MSH2
7 grade iii astrocytoma 32.9 TP53 PTEN IDH1 EGFR
8 meningioma, familial 32.6 TP53 PTEN IDH1 EGFR
9 gliosarcoma 32.5 TP53 PTEN IDH1 FGFR1 EGFR
10 medulloblastoma 32.4 TP53 PTEN PIK3CA NRAS MTOR MSH2
11 neuroblastoma 32.3 TP53 PTEN PIK3CA NRAS MTOR MSH2
12 neurofibromatosis, type iv, of riccardi 32.2 TP53 PTEN MTOR HRAS
13 gliomatosis cerebri 32.2 TP53 PTEN IDH1 EGFR BRAF
14 lung cancer susceptibility 3 32.2 TP53 PTEN PIK3CA NRAS MTOR MIR21
15 oligodendroglioma 32.2 TP53 PTEN PMS2 MSH2 IDH1 FGFR1
16 adenocarcinoma 32.2 TP53 PTEN PIK3CA MSH2 HRAS FGFR1
17 fibrillary astrocytoma 32.1 TP53 PTEN IDH1 EGFR
18 exanthem 32.1 MTOR HRAS EGFR
19 pleomorphic xanthoastrocytoma 32.0 TP53 IDH1 BRAF
20 mixed glioma 32.0 TP53 PTEN IDH1 EGFR
21 adenoma 31.9 TP53 PIK3CA MSH2 BRAF
22 brain glioma 31.9 TP53 IDH1 EGFR
23 myeloma, multiple 31.9 TP53 PTEN NRAS MTOR MIR21 MIR155
24 thyroid carcinoma 31.9 TP53 PTEN PIK3CA NRAS HRAS BRAF
25 lymphoma 31.9 TP53 PMS2 PIK3CA NRAS MSH2 FGFR1
26 sarcoma 31.9 TP53 PIK3CA NRAS MTOR MSH2 HRAS
27 gastric adenocarcinoma 31.8 TP53 PTEN PIK3CA NRAS MTOR HRAS
28 tuberous sclerosis 31.8 TP53 PTEN PIK3CA MTOR
29 basal cell carcinoma 31.7 TP53 PTEN MTOR MSH2 EGFR
30 squamous cell carcinoma 31.7 TP53 PTEN PIK3CA HRAS EGFR BRAF
31 gemistocytic astrocytoma 31.7 TP53 PTEN IDH1
32 thyroid gland cancer 31.7 TP53 PTEN PIK3CA NRAS MIR221 MIR21
33 brain stem glioma 31.7 TP53 PTEN PIK3CA IDH1 FGFR1 EGFR
34 bladder cancer 31.7 TP53 PTEN PIK3CA NRAS MIR221 MIR21
35 li-fraumeni syndrome 31.6 TP53 PTEN PMS2 MSH2 IDH1 HRAS
36 rhabdomyosarcoma 31.6 TP53 PTEN PMS2 MTOR MSH2 HRAS
37 colon adenocarcinoma 31.6 TP53 PTEN PMS2 PIK3CA MIR21 EGFR
38 cholangiocarcinoma 31.6 TP53 PTEN PIK3CA MTOR MIR21 IDH1
39 leukemia, chronic myeloid 31.6 TP53 PTEN NRAS MIR155 HRAS FGFR1
40 small cell cancer of the lung 31.6 TP53 PTEN PIK3CA MIR21 EGFR
41 leukemia, chronic lymphocytic 31.6 TP53 PTEN NRAS MIR221 MIR21 MIR155
42 retinitis pigmentosa 11 31.6 TP53 PTEN HRAS EGFR
43 small cell carcinoma 31.5 TP53 PTEN EGFR
44 lynch syndrome 31.5 TP53 PTEN PMS2 PIK3CA NRAS MSH2
45 hemangioma 31.5 TP53 PTEN MTOR IDH1
46 skin carcinoma 31.5 TP53 NRAS MSH2 MIR21 MIR149 HRAS
47 high-grade astrocytoma 31.5 PTEN IDH1
48 spitz nevus 31.5 TP53 HRAS BRAF
49 prostate cancer 31.5 TP53 PTEN PIK3CA MTOR MSH2 MIR221
50 supratentorial cancer 31.5 TP53 IDH1 EGFR
51 central nervous system cancer 31.5 TP53 PTEN MIR21 MIR155 MIR149 IDH1
52 nervous system cancer 31.5 TP53 PTEN MIR21 MIR155 MIR149 IDH1
53 melanoma 31.4 TP53 PTEN PIK3CA NRAS MTOR MIR221
54 esophagus adenocarcinoma 31.4 TP53 MIR21 EGFR
55 thymoma 31.4 TP53 PIK3CA MTOR HRAS EGFR
56 lymphoma, non-hodgkin, familial 31.4 TP53 PTEN PIK3CA NRAS MTOR MSH2
57 breast adenocarcinoma 31.4 TP53 PIK3CA IDH1 EGFR
58 muir-torre syndrome 31.3 TP53 PMS2 MSH2
59 intrahepatic cholangiocarcinoma 31.3 TP53 PTEN IDH1 EGFR
60 lymphoproliferative syndrome 31.3 NRAS MTOR MIR21 HRAS
61 kidney cancer 31.3 TP53 PTEN PIK3CA MTOR MIR210 MIR21
62 colorectal cancer 31.3 TP53 PTEN PMS2 PIK3CA NRAS MTOR
63 gastric cancer 31.3 TP53 PTEN PIK3CA NRAS MTOR MSH2
64 nasopharyngeal carcinoma 31.3 TP53 PTEN PIK3CA NRAS MTOR MIR21
65 myelofibrosis 31.3 TP53 MTOR IDH1 HRAS FGFR1
66 cervical cancer 31.2 TP53 PTEN PIK3CA MTOR MIR21 MIR155
67 breast cancer 31.2 TP53 PTEN PMS2 PIK3CA NRAS MTOR
68 t-cell leukemia 31.2 TP53 PTEN PIK3CA NRAS HRAS
69 gastrointestinal stromal tumor 31.2 TP53 PTEN MIR137 EGFR BRAF
70 hepatocellular carcinoma 31.2 TP53 PTEN PIK3CA NRAS MTOR MSH2
71 squamous cell papilloma 31.1 TP53 HRAS
72 neurofibroma 31.0 TP53 PTEN EGFR
73 leukemia, acute myeloid 31.0 TP53 PTEN NRAS MTOR MIR221 MIR210
74 adult astrocytic tumour 31.0 TP53 PTEN IDH1
75 adenoid cystic carcinoma 31.0 TP53 PTEN PIK3CA MTOR IDH1 HRAS
76 tongue cancer 31.0 TP53 PTEN MIR21 EGFR
77 pancreatic cancer 31.0 TP53 PTEN PIK3CA MTOR MSH2 MIR221
78 renal cell carcinoma, nonpapillary 31.0 TP53 PTEN PIK3CA NRAS MTOR MIR221
79 diffuse large b-cell lymphoma 30.9 TP53 PTEN MTOR MIR221 MIR210 MIR21
80 colorectal adenocarcinoma 30.9 TP53 PTEN PMS2 MSH2 HRAS EGFR
81 ovarian cancer 30.9 TP53 PTEN PMS2 PIK3CA MTOR MSH2
82 lung cancer 30.9 TP53 PTEN PIK3CA NRAS MTOR MIR221
83 esophageal cancer 30.9 TP53 PTEN PIK3CA MTOR MSH2 MIR21
84 skin melanoma 30.9 TP53 PTEN PMS2 NRAS HRAS BRAF
85 testicular germ cell tumor 30.9 TP53 PTEN HRAS
86 oral cancer 30.8 TP53 MIR21 EGFR
87 pancreatic ductal adenocarcinoma 30.8 TP53 PTEN MIR221 MIR210 MIR21 MIR155
88 lipomatosis 30.8 PTEN PIK3CA FGFR1
89 pilomyxoid astrocytoma 30.8 IDH1 FGFR1 BRAF
90 leukemia, acute lymphoblastic 30.8 PMS2 MIR221 MIR210 MIR21 MIR155 MIR128-1
91 pancreatic adenocarcinoma 30.7 TP53 PTEN PIK3CA MIR221 MIR210 MIR21
92 liposarcoma 30.7 TP53 PTEN PIK3CA MSH2 MIR155
93 acute promyelocytic leukemia 30.7 PTEN NRAS MIR221 MIR210 HRAS BCOR
94 nervous system disease 30.6 TP53 MIR221 MIR21 MIR155 MIR149
95 hematologic cancer 30.6 TP53 MTOR MSH2 MIR221 MIR21 MIR155
96 pilocytic astrocytoma of cerebellum 30.6 IDH1 BRAF
97 rosette-forming glioneuronal tumor 30.5 PIK3CA FGFR1
98 squamous cell carcinoma, head and neck 30.4 TP53 PTEN PIK3CA MIR221 MIR210 MIR21
99 muscular dystrophy, duchenne type 30.1 MIR221 MIR210 MIR21 MIR155
100 brain glioblastoma multiforme 12.7
101 adult spinal cord glioblastoma multiforme 12.6
102 goodpasture syndrome 12.3
103 anti-basement membrane glomerulonephritis 11.6
104 rapidly progressive glomerulonephritis 11.6
105 microvascular complications of diabetes 3 11.5
106 membranoproliferative glomerulonephritis 11.5
107 dense deposit disease 11.5
108 glioma susceptibility 2 11.4
109 glioma susceptibility 3 11.4
110 glioma susceptibility 9 11.4
111 glioblastoma classical subtype 11.4
112 glioblastoma proneural subtype 11.4
113 glioblastoma mesenchymal subtype 11.4
114 glioblastoma neural subtype 11.4
115 bladder urothelial carcinoma 11.4 TP53 PTEN PIK3CA NRAS MTOR IDH1
116 renal cell carcinoma, papillary, 1 11.4 TP53 PTEN PIK3CA NRAS MTOR MSH2
117 suppression of tumorigenicity 12 11.3 TP53 PTEN PIK3CA MTOR IDH1 HRAS
118 rare breast tumor 11.3 TP53 PTEN PIK3CA MTOR IDH1 HRAS
119 rare cancer of corpus uteri 11.3 TP53 PTEN PIK3CA NRAS MTOR HRAS
120 ovarian serous cystadenocarcinoma 11.3 TP53 PTEN PIK3CA NRAS HRAS EGFR
121 cell type benign neoplasm 11.3 TP53 PTEN PIK3CA MTOR MSH2 MIR21
122 lung squamous cell carcinoma 11.3 TP53 PTEN PIK3CA MTOR HRAS FGFR1
123 obsolete: squamous cell carcinoma of head and neck 11.2 TP53 PTEN PIK3CA HRAS EGFR BRAF
124 thyroid tumor 11.2 TP53 PTEN PIK3CA NRAS HRAS BRAF
125 bile duct adenocarcinoma 11.2 TP53 PTEN MIR21 IDH1 HRAS EGFR
126 serous cystadenocarcinoma 11.2 TP53 PTEN PIK3CA NRAS HRAS BRAF
127 melanoma, uveal 11.2 TP53 PTEN NRAS MIR149 HRAS EGFR
128 chordoma 11.2 TP53 PTEN MTOR IDH1 EGFR
129 transitional cell carcinoma 11.2 TP53 PTEN MSH2 HRAS EGFR BRAF
130 cowden syndrome 1 11.2 TP53 PTEN PIK3CA MTOR MSH2 EGFR
131 luminal breast carcinoma 11.2 TP53 PTEN PIK3CA MTOR MIR21 EGFR
132 ovary adenocarcinoma 11.2 TP53 PTEN PIK3CA MSH2 HRAS EGFR
133 uterine carcinosarcoma 11.2 TP53 PTEN PIK3CA MSH2 HRAS EGFR
134 malignant ovarian surface epithelial-stromal neoplasm 11.2 TP53 PTEN PIK3CA MIR21 HRAS EGFR
135 ovary epithelial cancer 11.2 TP53 PTEN PIK3CA MIR21 HRAS EGFR
136 uterine body mixed cancer 11.2 TP53 PTEN PIK3CA HRAS EGFR
137 differentiated thyroid carcinoma 11.2 TP53 NRAS HRAS EGFR BRAF
138 mixed cell type cancer 11.2 TP53 PTEN PIK3CA HRAS EGFR
139 uterine corpus cancer 11.2 TP53 PTEN PIK3CA HRAS EGFR
140 carcinosarcoma 11.2 TP53 PTEN PIK3CA HRAS EGFR
141 ovarian cystadenocarcinoma 11.2 TP53 PTEN PIK3CA HRAS EGFR
142 oropharynx cancer 11.2 TP53 PTEN PIK3CA HRAS EGFR
143 pre-malignant neoplasm 11.2 TP53 PTEN PIK3CA HRAS EGFR
144 penile cancer 11.2 TP53 PTEN PIK3CA HRAS EGFR
145 vulvar disease 11.2 TP53 PIK3CA NRAS HRAS EGFR
146 hematuria, benign familial 11.2
147 juvenile myelomonocytic leukemia 11.2 TP53 PTEN NRAS HRAS BRAF
148 cystadenocarcinoma 11.2 TP53 PIK3CA NRAS HRAS BRAF
149 muscular disease 11.2 TP53 PTEN MTOR MIR221 HRAS EGFR
150 central nervous system benign neoplasm 11.2 TP53 PTEN MTOR IDH1
151 thymus gland disease 11.2 TP53 PTEN MTOR EGFR
152 thymus cancer 11.2 TP53 PTEN MTOR EGFR
153 skin papilloma 11.1 TP53 PTEN HRAS EGFR
154 respiratory system benign neoplasm 11.1 TP53 PTEN HRAS EGFR
155 lung adenoma 11.1 TP53 PTEN HRAS EGFR
156 infratentorial cancer 11.1 TP53 PTEN IDH1 EGFR
157 in situ carcinoma 11.1 TP53 PTEN HRAS EGFR
158 uterine corpus endometrial carcinoma 11.1 TP53 PTEN PIK3CA IDH1
159 thyroid gland anaplastic carcinoma 11.1 TP53 PTEN PIK3CA BRAF
160 oral cavity cancer 11.1 TP53 PTEN PIK3CA MIR21 EGFR
161 nodular malignant melanoma 11.1 TP53 NRAS HRAS BRAF
162 vulva cancer 11.1 TP53 PTEN PIK3CA EGFR
163 endometrial cancer 11.1 TP53 PTEN PMS2 PIK3CA NRAS MTOR
164 rasopathy 11.1 NRAS HRAS EGFR BRAF
165 adenosquamous carcinoma 11.1 TP53 PTEN PIK3CA EGFR
166 autonomic nervous system neoplasm 11.1 TP53 PTEN MIR149 HRAS EGFR
167 anus cancer 11.1 TP53 PIK3CA HRAS EGFR
168 peripheral nervous system neoplasm 11.1 TP53 PTEN MIR149 HRAS EGFR
169 estrogen-receptor positive breast cancer 11.1 TP53 PIK3CA MTOR EGFR
170 thyroid cancer, nonmedullary, 2 11.1 PTEN NRAS HRAS BRAF
171 adrenocortical carcinoma, hereditary 11.1 TP53 PIK3CA NRAS BRAF
172 ductal carcinoma in situ 11.1 TP53 PTEN PIK3CA EGFR
173 frontal lobe neoplasm 11.1 TP53 IDH1 EGFR
174 tongue disease 11.1 TP53 PTEN MIR21 EGFR
175 spinal cord oligodendroglioma 11.1 TP53 IDH1 FGFR1 EGFR
176 keratosis 11.1 TP53 PIK3CA HRAS EGFR
177 nevus, epidermal 11.1 PTEN PIK3CA NRAS HRAS FGFR1
178 melanoma, cutaneous malignant 1 11.1 TP53 PTEN PMS2 PIK3CA NRAS MSH2
179 laryngeal squamous cell carcinoma 11.1 TP53 PTEN MIR21 EGFR
180 skin squamous cell carcinoma 11.1 TP53 PTEN PMS2 NRAS MSH2 HRAS
181 cowden syndrome 11.1 TP53 PTEN PMS2 PIK3CA MTOR MSH2
182 juvenile astrocytoma 11.1 TP53 IDH1 BRAF
183 paronychia 11.1 MTOR HRAS EGFR
184 cerebrum cancer 11.1 TP53 IDH1 EGFR
185 breast carcinoma in situ 11.1 TP53 PTEN FGFR1 EGFR
186 acneiform dermatitis 11.1 NRAS HRAS EGFR
187 thoracic benign neoplasm 11.1 TP53 IDH1 EGFR
188 breast benign neoplasm 11.1 TP53 IDH1 EGFR
189 verrucous carcinoma 11.1 TP53 PTEN EGFR
190 tongue squamous cell carcinoma 11.1 TP53 PTEN MIR21 EGFR
191 bile duct cancer 11.1 TP53 PTEN HRAS EGFR
192 breast squamous cell carcinoma 11.1 TP53 PIK3CA HRAS
193 benign struma ovarii 11.0 NRAS HRAS BRAF
194 cervical mucinous adenocarcinoma 11.0 TP53 PTEN MSH2
195 uterine corpus serous adenocarcinoma 11.0 TP53 PTEN PIK3CA
196 acral lentiginous melanoma 11.0 PTEN NRAS BRAF
197 proteus syndrome 11.0 PTEN PIK3CA MTOR FGFR1
198 large cell carcinoma 11.0 MTOR HRAS FGFR1 EGFR
199 hypertrophy of breast 11.0 TP53 PTEN PIK3CA
200 lip cancer 11.0 TP53 MSH2 BRAF
201 thyroid gland follicular carcinoma 11.0 TP53 PTEN HRAS
202 colorectal adenoma 11.0 TP53 MSH2 MIR21 HRAS
203 uterine benign neoplasm 11.0 TP53 PTEN HRAS
204 reproductive organ benign neoplasm 11.0 TP53 PTEN HRAS
205 laryngeal benign neoplasm 11.0 TP53 MIR21 EGFR
206 keratosis, seborrheic 11.0 TP53 PIK3CA MTOR
207 erdheim-chester disease 11.0 PIK3CA NRAS BRAF
208 gallbladder adenocarcinoma 11.0 TP53 PIK3CA EGFR
209 astrocytoma 11.0
210 ovarian clear cell adenocarcinoma 11.0 TP53 PIK3CA MTOR
211 intestinal benign neoplasm 11.0 TP53 PTEN PMS2 PIK3CA MSH2 MIR21
212 autoimmune lymphoproliferative syndrome 11.0 NRAS MTOR MIR21 HRAS
213 laryngeal disease 11.0 TP53 MIR21 MIR149 EGFR
214 ovarian disease 11.0 TP53 PTEN PMS2 PIK3CA MSH2 MIR21
215 duodenum disease 11.0 TP53 MSH2 HRAS
216 melanocytic nevus syndrome, congenital 11.0 NRAS MSH2 HRAS
217 familial colorectal cancer 11.0 TP53 MSH2 BRAF
218 lung benign neoplasm 11.0 TP53 HRAS EGFR
219 signet ring cell adenocarcinoma 11.0 TP53 MSH2 HRAS
220 nevus of ota 11.0 TP53 BRAF
221 uterine anomalies 11.0 TP53 PTEN MIR221 MIR21 MIR149
222 spitzoid melanoma 11.0 HRAS BRAF
223 keratoacanthoma 11.0 TP53 MSH2 EGFR
224 ovarian clear cell carcinoma 11.0 TP53 PTEN PIK3CA
225 autosomal genetic disease 11.0 TP53 PTEN PMS2 MTOR MSH2 MIR21
226 endometrial adenocarcinoma 11.0 TP53 PTEN EGFR
227 connective tissue cancer 11.0 TP53 MIR21 MIR149 EGFR
228 sporadic breast cancer 11.0 TP53 PTEN EGFR
229 selection of therapeutic option in melanoma 11.0 NRAS BRAF
230 selection of therapeutic option in colorectal cancer 11.0 NRAS BRAF
231 vulvar seborrheic keratosis 11.0 PTEN MTOR
232 glomerulonephritis 11.0
233 colonic benign neoplasm 11.0 TP53 PMS2 MSH2 HRAS EGFR BRAF
234 thyroid hurthle cell adenoma 11.0 PTEN PIK3CA
235 costello syndrome 11.0 PIK3CA HRAS BRAF
236 contractures, pterygia, and variable skeletal fusions syndrome 1a 11.0 TP53 PTEN PMS2 MTOR MSH2 HRAS
237 skin benign neoplasm 11.0 MSH2 HRAS BRAF
238 melphalan allergy 11.0 NRAS BRAF
239 cardiofaciocutaneous syndrome 1 11.0 NRAS HRAS BRAF
240 breast duct papilloma 11.0 PTEN IDH1
241 rare head and neck tumor 11.0 TP53 PIK3CA
242 gallbladder cancer 11.0 TP53 PTEN PIK3CA EGFR
243 endometrioid ovary carcinoma 11.0 TP53 PTEN PMS2 PIK3CA MSH2 HRAS
244 melanoma in congenital melanocytic nevus 11.0 NRAS BRAF
245 female reproductive endometrioid cancer 11.0 TP53 PTEN PMS2 PIK3CA MSH2 HRAS
246 rectum adenocarcinoma 11.0 TP53 PMS2 PIK3CA MSH2 HRAS EGFR
247 peutz-jeghers syndrome 10.9 TP53 PTEN EGFR
248 ovarian clear cell adenofibroma 10.9 PTEN PIK3CA
249 cervical adenocarcinoma 10.9 TP53 PTEN EGFR
250 hyperplastic polyposis syndrome 10.9 TP53 BRAF
251 esophageal basaloid squamous cell carcinoma 10.9 TP53 EGFR
252 esophagus verrucous carcinoma 10.9 TP53 EGFR
253 alveolar soft part sarcoma 10.9 MTOR MSH2 EGFR
254 gastrointestinal system benign neoplasm 10.9 TP53 PMS2 MSH2 MIR21 HRAS EGFR
255 actinic cheilitis 10.9 TP53 MSH2
256 malignant glioma 10.9
257 renal pelvis transitional cell carcinoma 10.9 MTOR MSH2
258 malignant anus melanoma 10.9 NRAS HRAS
259 endometrial hyperplasia 10.9 TP53 PTEN MSH2
260 follicular adenoma 10.9 PTEN MIR221 BRAF
261 leopard syndrome 10.9 PIK3CA HRAS BRAF
262 systemic mastocytosis 10.9 NRAS IDH1 FGFR1
263 bladder disease 10.9 TP53 MIR221 MIR21 MIR149
264 rare adenocarcinoma of the breast 10.9 TP53 PIK3CA
265 myeloproliferative neoplasm 10.9 NRAS MIR155 IDH1 HRAS FGFR1 EGFR
266 mantle cell lymphoma 10.9 TP53 PTEN PIK3CA MTOR MIR155
267 parameningeal embryonal rhabdomyosarcoma 10.8 TP53 PIK3CA NRAS BCOR
268 adult teratoma 10.8 TP53 HRAS
269 small intestine cancer 10.8 TP53 PMS2 MSH2 HRAS
270 hereditary breast ovarian cancer syndrome 10.8 TP53 PTEN PMS2 MSH2
271 skin lipoma 10.8 PTEN FGFR1
272 pancreas disease 10.8 TP53 MIR221 MIR21 MIR155 MIR149 HRAS
273 colonic disease 10.8 TP53 MIR221 MIR21 MIR155 MIR149 HRAS
274 central nervous system melanocytic neoplasm 10.8 NRAS HRAS
275 thyroid gland disease 10.8 TP53 PTEN MIR221 MIR210 MIR21 MIR149
276 eccrine papillary adenoma 10.8 PIK3CA HRAS
277 breast hemangioma 10.8 TP53 IDH1
278 malignant dermis tumor 10.8 NRAS HRAS
279 colorectal cancer, hereditary nonpolyposis, type 5 10.8 PMS2 MSH2 BRAF
280 small intestine adenocarcinoma 10.8 PMS2 MSH2 HRAS
281 myh-associated polyposis 10.8 MSH2 HRAS
282 duodenum adenocarcinoma 10.8 PMS2 MSH2 HRAS
283 sebaceous adenocarcinoma 10.8 TP53 PMS2 MSH2
284 bone marrow cancer 10.8 TP53 MIR21 MIR155 HRAS
285 malignant skin fibrous histiocytoma 10.8 NRAS HRAS
286 duodenum cancer 10.7 PMS2 MSH2 HRAS
287 mucinous lung adenocarcinoma 10.7 HRAS EGFR
288 juvenile polyposis syndrome 10.7 PTEN PMS2 MSH2
289 breast disease 10.7 TP53 MSH2 MIR221 MIR21 MIR155
290 bone osteosarcoma 10.7 TP53 MIR221 BCOR
291 dermatosis papulosa nigra 10.7 PIK3CA MTOR
292 splenic diffuse red pulp small b-cell lymphoma 10.7 TP53 BCOR
293 endocrine organ benign neoplasm 10.7 TP53 MIR221 MIR210 MIR21
294 female reproductive system disease 10.7 TP53 MIR221 MIR21 MIR155 MIR149
295 thoracic cancer 10.7 TP53 MIR221 MIR21 MIR155 MIR149
296 intestinal disease 10.7 TP53 MIR221 MIR21 MIR155 MIR149
297 leukocyte disease 10.7 TP53 MIR21 MIR155 MIR149
298 large intestine cancer 10.7 MIR221 MIR21 MIR155 MIR149 HRAS
299 meningioma, radiation-induced 10.7
300 spinal meningioma 10.7
301 secretory meningioma 10.7
302 lymphoplasmacyte-rich meningioma 10.7
303 adenosquamous colon carcinoma 10.7 PMS2 MSH2
304 neutropenia 10.7
305 clear cell renal cell carcinoma 10.7 TP53 PTEN MTOR MIR210 MIR21 MIR155
306 periampullary adenoma 10.7 PMS2 HRAS
307 rectum signet ring adenocarcinoma 10.7 PMS2 MSH2
308 extrahepatic bile duct adenoma 10.6 PMS2 MSH2
309 appendix carcinoid tumor 10.6 PMS2 MSH2
310 hydrocephalus 10.6
311 male reproductive system disease 10.6 MIR221 MIR21 MIR155 MIR149
312 reproductive system disease 10.6 MIR221 MIR21 MIR155 MIR149
313 gonadal disease 10.6 TP53 MIR221 MIR21 MIR155
314 rare surgical neurologic disease 10.6
315 crescentic glomerulonephritis 10.6
316 jejunal cancer 10.6 PMS2 MSH2
317 vasculitis 10.6
318 oral squamous cell carcinoma 10.6 TP53 MIR221 MIR21 MIR155 MIR137 MIR128-1
319 wolffian duct adenocarcinoma 10.6 TP53 HRAS
320 male reproductive organ cancer 10.5 MIR221 MIR21 MIR155 MIR149
321 prostate disease 10.5 MIR221 MIR21 MIR155 MIR149
322 thrombocytopenia 10.5
323 endocrine gland cancer 10.5 MIR221 MIR21 MIR155 MIR149
324 lymphocytic leukemia 10.5
325 intracranial hypertension 10.5
326 pulmonary embolism 10.5
327 cell type cancer 10.5 TP53 MIR221 MIR210 MIR21 MIR155 MIR149
328 adult oligodendroglioma 10.4 IDH1 FGFR1
329 brain edema 10.4
330 lymphopenia 10.4
331 headache 10.4
332 respiratory system cancer 10.4 MIR221 MIR210 MIR21 MIR155 MIR149 EGFR
333 respiratory system disease 10.4 MIR221 MIR210 MIR21 MIR155 MIR149 EGFR
334 gastrointestinal system cancer 10.4 MIR221 MIR21 MIR155 MIR149
335 aphasia 10.4
336 severe combined immunodeficiency 10.4
337 hypoxia 10.4
338 membranous nephropathy 10.4
339 polymyositis 10.4 MIR221 MIR210 MIR21 MIR155
340 miyoshi muscular dystrophy 1 10.4 MIR221 MIR210 MIR21 MIR155
341 diphtheria 10.4
342 herpes simplex 10.4
343 low-grade astrocytoma 10.4
344 rare tumor 10.4
345 dermatomyositis 10.4 MIR221 MIR210 MIR21 MIR155
346 systemic lupus erythematosus 10.4
347 alport syndrome 10.4
348 obsolete: rapidly progressive glomerulonephritis 10.4
349 urinary system disease 10.4 MIR221 MIR210 MIR21 MIR155 MIR149
350 retinoblastoma 10.4
351 thrombophilia due to thrombin defect 10.4
352 ataxia and polyneuropathy, adult-onset 10.4
353 hydrops, lactic acidosis, and sideroblastic anemia 10.4
354 visual epilepsy 10.4
355 familial retinoblastoma 10.4
356 seizure disorder 10.4
357 endocrine system disease 10.4 MIR221 MIR210 MIR21 MIR155 MIR149
358 end stage renal failure 10.3
359 anca-associated vasculitis 10.3
360 vulvar melanoma 10.3 NRAS HRAS
361 arteries, anomalies of 10.3 MIR221 MIR210 MIR21 MIR155
362 paraplegia 10.3
363 encephalitis 10.3
364 alopecia 10.3
365 glomerular disease 10.3
366 connective tissue disease 10.3 MIR221 MIR210 MIR21 MIR155 MIR149
367 gastrointestinal system disease 10.3 MIR221 MIR21 MIR155 MIR149
368 neurilemmoma 10.3
369 central nervous system lymphoma 10.3
370 benign ependymoma 10.3
371 juvenile pilocytic astrocytoma 10.3
372 b-cell lymphoma 10.3
373 meningitis 10.3
374 cytokine deficiency 10.3
375 back pain 10.3
376 kidney disease 10.3
377 acoustic neuroma 10.3
378 papilledema 10.3
379 newcastle disease 10.3
380 teratoma 10.3
381 ganglioglioma 10.3
382 cellular ependymoma 10.3
383 stomatitis 10.3
384 anaplastic oligodendroglioma 10.3
385 primary central nervous system lymphoma 10.3
386 polyploidy 10.3
387 microvascular complications of diabetes 4 10.2
388 microvascular complications of diabetes 6 10.2
389 microvascular complications of diabetes 7 10.2
390 nephrotic syndrome 10.2
391 iga glomerulonephritis 10.2
392 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.2
393 immune deficiency disease 10.2
394 ocular motor apraxia 10.2
395 deficiency anemia 10.2
396 arteriovenous malformation 10.2
397 obstructive hydrocephalus 10.2
398 status epilepticus 10.2
399 fibrosarcoma 10.2
400 chromosomal triplication 10.2
401 cytomegalovirus infection 10.2
402 specific language disorder 10.2
403 48,xyyy 10.2
404 hepatitis a 10.1
405 immune-complex glomerulonephritis 10.1
406 lupus erythematosus 10.1
407 diffuse alveolar hemorrhage 10.1
408 alzheimer disease 10.1
409 triiodothyronine receptor auxiliary protein 10.1
410 wilms tumor 1 10.1
411 lymphoma, hodgkin, classic 10.1
412 proteasome-associated autoinflammatory syndrome 1 10.1
413 osteogenic sarcoma 10.1
414 insulin-like growth factor i 10.1
415 stroke, ischemic 10.1
416 wilms tumor 5 10.1
417 aplastic anemia 10.1
418 aspergillosis 10.1
419 myelodysplastic syndrome 10.1
420 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.1
421 apraxia 10.1
422 cysticercosis 10.1
423 hemiplegia 10.1
424 pancytopenia 10.1
425 polyneuropathy 10.1
426 gonadal dysgenesis 10.1
427 communicating hydrocephalus 10.1
428 epilepsy 10.1
429 optic nerve disease 10.1
430 neuroma 10.1
431 cystic teratoma 10.1
432 turner syndrome 10.1
433 hyperglycemia 10.1
434 cerebral lymphoma 10.1
435 acquired immunodeficiency syndrome 10.1
436 cerebrovascular disease 10.1
437 transitional meningioma 10.1
438 measles 10.1
439 subacute delirium 10.1
440 hypoglycemia 10.1
441 multiple sclerosis 10.1
442 helix syndrome 10.1
443 anuria 10.1
444 proliferative glomerulonephritis 10.1
445 amyloidosis 10.1
446 neurofibromatosis, type ii 10.1
447 hypercholesterolemia, familial, 1 10.1
448 neurofibromatosis, type i 10.1
449 ataxia-telangiectasia 10.1
450 cystic fibrosis 10.1
451 intracranial hypertension, idiopathic 10.1
452 thrombocytopenia 1 10.1
453 asthma 10.1
454 langerhans cell histiocytosis 10.1
455 li-fraumeni syndrome 2 10.1
456 familial adenomatous polyposis 10.1
457 cerebellar medulloblastoma 10.1
458 benign teratoma 10.1
459 intracranial aneurysm 10.1
460 respiratory failure 10.1
461 disseminated intravascular coagulation 10.1
462 cauda equina syndrome 10.1
463 optic neuritis 10.1
464 acute leukemia 10.1
465 telangiectasis 10.1
466 rheumatic disease 10.1
467 vascular cancer 10.1
468 neuritis 10.1
469 enthesopathy 10.1
470 hepatitis b 10.1
471 transient cerebral ischemia 10.1
472 sensory peripheral neuropathy 10.1
473 idiopathic interstitial pneumonia 10.1
474 histiocytosis 10.1
475 cerebritis 10.1
476 lactic acidosis 10.1
477 pulmonary fibrosis 10.1
478 thrombophlebitis 10.1
479 spindle cell sarcoma 10.1
480 radiculopathy 10.1
481 mature teratoma 10.1
482 combined t cell and b cell immunodeficiency 10.1
483 toxoplasmosis 10.1
484 47,xyy 10.1
485 allergic encephalomyelitis 10.1
486 granulocytopenia 10.1
487 herpes simplex encephalitis 10.1
488 oligoastrocytoma 10.1
489 depression 10.1
490 head injury 10.1
491 syncope 10.1
492 nemaline myopathy 10.0 MIR221 MIR210 MIR155
493 rhabdoid tumor predisposition syndrome 1 10.0
494 rhabdoid cancer 10.0
495 down syndrome 10.0
496 alport syndrome 1, x-linked 10.0
497 branchiootic syndrome 1 10.0
498 autoimmune glomerulonephritis 10.0
499 pyelonephritis 10.0
500 peripheral nervous system disease 10.0
501 neuropathy 10.0
502 hypophosphatemia 10.0
503 thalassemia 10.0
504 tetanus 10.0
505 cholera 10.0
506 embryoma 10.0
507 polykaryocytosis inducer 9.9
508 alpha-thalassemia 9.9
509 leukemia, acute lymphoblastic 3 9.9
510 papilloma 9.9
511 dysphagia 9.9
512 abducens palsy 9.9
513 alcohol dependence 9.9
514 cerebral amyloid angiopathy, cst3-related 9.9
515 amyotrophic lateral sclerosis 1 9.9
516 autoimmune disease 9.9
517 cerebral cavernous malformations 9.9
518 colchicine resistance 9.9
519 huntington disease 9.9
520 hypertriglyceridemia, familial 9.9
521 intussusception 9.9
522 klippel-trenaunay-weber syndrome 9.9
523 metaphyseal chondrodysplasia, schmid type 9.9
524 neutrophil migration 9.9
525 otitis media 9.9
526 teratoma, ovarian 9.9
527 parkinson disease, late-onset 9.9
528 pheochromocytoma 9.9
529 sarcoidosis 1 9.9
530 thyroid cancer, nonmedullary, 1 9.9
531 trigeminal neuralgia 9.9
532 tuberous sclerosis 1 9.9
533 varicose veins 9.9
534 arachnoid cysts, intracranial 9.9
535 celiac disease 1 9.9
536 charge syndrome 9.9
537 chondrosarcoma 9.9
538 leukoencephalopathy, hereditary diffuse, with spheroids 9.9
539 factor vii deficiency 9.9
540 hydrocephalus, congenital, 1 9.9
541 hydrocephalus due to congenital stenosis of aqueduct of sylvius 9.9
542 hypoascorbemia 9.9
543 tubulin, beta 9.9
544 yemenite deaf-blind hypopigmentation syndrome 9.9
545 fanconi anemia, complementation group d1 9.9
546 body mass index quantitative trait locus 1 9.9
547 allergic rhinitis 9.9
548 anxiety 9.9
549 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
550 cortical dysplasia, complex, with other brain malformations 7 9.9
551 glioma susceptibility 5 9.9
552 tumor predisposition syndrome 9.9
553 hyperprolactinemia 9.9
554 pachyonychia congenita 3 9.9
555 autoimmune lymphoproliferative syndrome, type v 9.9
556 thrombocytopenia 6 9.9
557 phenytoin toxicity 9.9
558 adrenal gland pheochromocytoma 9.9
559 cardiac arrest 9.9
560 dental abscess 9.9
561 pollen allergy 9.9
562 spinal disease 9.9
563 thrombosis 9.9
564 childhood acute lymphocytic leukemia 9.9
565 mucositis 9.9
566 asymptomatic neurosyphilis 9.9
567 intracranial abscess 9.9
568 cerebral artery occlusion 9.9
569 osteonecrosis 9.9
570 parotitis 9.9
571 chronic meningitis 9.9
572 bacterial infectious disease 9.9
573 rickets 9.9
574 interstitial nephritis 9.9
575 renal hypertension 9.9
576 thrombotic thrombocytopenic purpura 9.9
577 discitis 9.9
578 rabies 9.9
579 subdural empyema 9.9
580 heart disease 9.9
581 autonomic neuropathy 9.9
582 splenic sequestration 9.9
583 allergic hypersensitivity disease 9.9
584 aseptic meningitis 9.9
585 leukemia 9.9
586 quadriplegia 9.9
587 guillain-barre syndrome 9.9
588 carotid stenosis 9.9
589 acute cystitis 9.9
590 cholestasis 9.9
591 facial paralysis 9.9
592 central neurocytoma 9.9
593 capillary leak syndrome 9.9
594 hypothyroidism 9.9
595 cystitis 9.9
596 calcinosis 9.9
597 malignant fibroxanthoma 9.9
598 gaucher's disease 9.9
599 leiomyosarcoma 9.9
600 rectum cancer 9.9
601 constipation 9.9
602 focal epilepsy 9.9
603 hepatitis 9.9
604 lateral sclerosis 9.9
605 granular cell tumor 9.9
606 gangliocytoma 9.9
607 acromegaly 9.9
608 benign mesothelioma 9.9
609 sebaceous adenoma 9.9
610 dysembryoplastic neuroepithelial tumor 9.9
611 renal adenoma 9.9
612 dermatitis 9.9
613 tic disorder 9.9
614 testicular cancer 9.9
615 acute kidney failure 9.9
616 interstitial lung disease 9.9
617 spinal cord glioma 9.9
618 neurilemmoma of the fifth cranial nerve 9.9
619 demyelinating disease 9.9
620 ischemia 9.9
621 chronic granulomatous disease 9.9
622 mood disorder 9.9
623 purpura 9.9
624 temporal lobe epilepsy 9.9
625 choroid plexus cancer 9.9
626 plasmacytoma 9.9
627 pleural empyema 9.9
628 pituitary adenoma 9.9
629 thyroid gland papillary carcinoma 9.9
630 cerebral neuroblastoma 9.9
631 histiocytoma 9.9
632 polyradiculopathy 9.9
633 tinea capitis 9.9
634 fibrous histiocytoma 9.9
635 dysgraphia 9.9
636 benign meningioma 9.9
637 ulnar neuropathy 9.9
638 cerebellar astrocytoma 9.9
639 spinal cord astrocytoma 9.9
640 poliomyelitis 9.9
641 gerstmann syndrome 9.9
642 optic nerve glioma 9.9
643 malignant ependymoma 9.9
644 subependymal giant cell astrocytoma 9.9
645 demyelinating polyneuropathy 9.9
646 hemangioblastoma 9.9
647 pneumonia 9.9
648 ovarian germ cell teratoma 9.9
649 hemolytic anemia 9.9
650 congestive heart failure 9.9
651 epithelioid sarcoma 9.9
652 fibromyalgia 9.9
653 acute disseminated encephalomyelitis 9.9
654 progressive multifocal leukoencephalopathy 9.9
655 prion disease 9.9
656 cerebral angioma 9.9
657 parasagittal meningioma 9.9
658 meningothelial meningioma 9.9
659 childhood leukemia 9.9
660 hyperthyroidism 9.9
661 cataract 9.9
662 polyhydramnios 9.9
663 lung disease 9.9
664 hodgkin's lymphoma, lymphocytic-histiocytic predominance 9.9
665 myeloid leukemia 9.9
666 dermatophytosis 9.9
667 scotoma 9.9
668 exophthalmos 9.9
669 postpartum depression 9.9
670 pathologic nystagmus 9.9
671 acquired hemophilia 9.9
672 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.9
673 anaplastic ganglioglioma 9.9
674 anaplastic oligoastrocytoma 9.9
675 central congenital hypothyroidism 9.9
676 cerebrospinal fluid leak 9.9
677 chronic hiccups 9.9
678 cluster headache 9.9
679 dendritic cell tumor 9.9
680 desmoplastic infantile ganglioglioma 9.9
681 diffuse intrinsic pontine glioma 9.9
682 gigantism 9.9
683 hemimegalencephaly 9.9
684 heparin-induced thrombocytopenia 9.9
685 limbic encephalitis 9.9
686 neurosyphilis 9.9
687 soft tissue sarcoma 9.9
688 spastic paraparesis 9.9
689 subependymoma 9.9
690 undifferentiated pleomorphic sarcoma 9.9
691 weber syndrome 9.9
692 aneurysm 9.9
693 anoxia 9.9
694 cerebral aneurysms 9.9
695 cerebral atrophy 9.9
696 paresthesia 9.9
697 pituitary tumors 9.9
698 traumatic brain injury 9.9
699 whiplash 9.9
700 angioosteohypertrophic syndrome 9.9
701 b-cell non-hodgkin lymphoma 9.9
702 rapidly involuting congenital hemangioma 9.9
703 inflammatory myopathy with abundant macrophages 9.9
704 argyria 9.9
705 pik3ca-related overgrowth syndrome 9.9
706 neurometabolic disease 9.9
707 monosomy 22 9.9
708 thrombotic microangiopathy 9.9
709 refractory anemia 9.9
710 alpha-thalassemia/mental retardation syndrome, x-linked 9.9
711 tatton-brown-rahman syndrome 9.9
712 microcephaly 9.9
713 vascular disease 9.9
714 vaccinia 9.9
715 craniopharyngioma 9.9
716 germ cells tumors 9.9
717 overgrowth syndrome 9.9
718 pernicious anemia 9.8
719 rheumatoid arthritis 9.8
720 scleroderma, familial progressive 9.8
721 hemochromatosis, type 1 9.8
722 pierson syndrome 9.8
723 dengue virus 9.8
724 invasive aspergillosis 9.8
725 t-cell large granular lymphocyte leukemia 9.8
726 renal fibrosis 9.8
727 autosomal recessive alport syndrome 9.8
728 x-linked alport syndrome 9.8
729 castleman disease 9.8
730 malignant hypertension 9.8
731 lipoid nephrosis 9.8
732 xanthogranulomatous pyelonephritis 9.8
733 mononeuropathy 9.8
734 primary biliary cirrhosis 9.8
735 hemolytic-uremic syndrome 9.8
736 focal segmental glomerulosclerosis 9.8
737 diarrhea 9.8
738 impotence 9.8
739 viral hepatitis 9.8
740 churg-strauss syndrome 9.8
741 mesenchymal cell neoplasm 9.8
742 systemic scleroderma 9.8
743 rhinitis 9.8
744 uremia 9.8
745 liver cirrhosis 9.8
746 complement deficiency 9.8
747 chronic kidney disease 9.8
748 cocaine abuse 9.8
749 malignant histiocytosis 9.8
750 hypereosinophilic syndrome 9.8
751 allergic angiitis 9.8
752 amyloidosis aa 9.8
753 microscopic polyangiitis 9.8
754 encephalopathy 9.8
755 histiocytic sarcoma 9.8
756 pauci-immune glomerulonephritis 9.8
757 keratitis, hereditary 9.8
758 fanconi anemia, complementation group d2 9.8
759 papilloma of choroid plexus 9.8
760 human immunodeficiency virus type 1 9.8
761 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
762 japanese encephalitis 9.8
763 lymphocytic choriomeningitis 9.8
764 intestinal perforation 9.8
765 thrombocytosis 9.8
766 myelitis 9.8
767 germinoma 9.8
768 macroglobulinemia 9.8
769 transverse myelitis 9.8
770 multiple system atrophy 1 9.7
771 ige responsiveness, atopic 9.7
772 migraine with or without aura 1 9.7
773 neural tube defects 9.7
774 torticollis 9.7
775 fanconi anemia, complementation group a 9.7
776 3-methylglutaconic aciduria, type iii 9.7
777 thymoma, familial 9.7
778 hemophagocytic lymphohistiocytosis, familial, 2 9.7
779 migraine with or without aura 3 9.7
780 retinitis pigmentosa 30 9.7
781 hepatitis c virus 9.7
782 west nile virus 9.7
783 microvascular complications of diabetes 5 9.7
784 generalized epilepsy with febrile seizures plus 9.7
785 agraphia 9.7
786 mastoiditis 9.7
787 nut midline carcinoma 9.7
788 amnestic disorder 9.7
789 pertussis 9.7
790 locked-in syndrome 9.7
791 alexia 9.7
792 multiple cranial nerve palsy 9.7
793 alcohol use disorder 9.7
794 neuroendocrine tumor 9.7
795 hepatitis c 9.7
796 encephalomalacia 9.7
797 brain germinoma 9.7
798 atypical teratoid rhabdoid tumor 9.7
799 relapsing-remitting multiple sclerosis 9.7
800 severe acute respiratory syndrome 9.7
801 neurilemmomatosis 9.7
802 central nervous system disease 9.7
803 choriocarcinoma 9.7
804 central nervous system germinoma 9.7
805 malignant peripheral nerve sheath tumor 9.7
806 spinal stenosis 9.7
807 diabetes insipidus 9.7
808 muscular dystrophy 9.7
809 anaplastic ependymoma 9.7
810 anaplastic pleomorphic xanthoastrocytoma 9.7
811 brain tumor, childhood 9.7
812 hansen's disease 9.7
813 primary angiitis of the central nervous system 9.7
814 posttransplant acute limbic encephalitis 9.7
815 obsolete: atypical teratoid/rhabdoid tumor 9.7
816 arteriovenous malformations of the brain 9.6
817 burkitt lymphoma 9.6
818 coloboma of macula 9.6
819 creutzfeldt-jakob disease 9.6
820 epidermoid cysts 9.6
821 pilomatrixoma 9.6
822 facial spasm 9.6
823 lipomatosis, multiple 9.6
824 mesothelioma, malignant 9.6
825 antigen defined by monoclonal antibody aj9 9.6
826 nondisjunction 9.6
827 enchondromatosis, multiple, ollier type 9.6
828 paragangliomas 1 9.6
829 polycystic kidney disease 1 with or without polycystic liver disease 9.6
830 palmoplantar keratoderma, punctate type ii 9.6
831 proline-negative auxotroph of hamster, complementation of 9.6
832 retinal detachment 9.6
833 schistosoma mansoni infection, susceptibility/ 9.6
834 schizophrenia 1 9.6
835 strabismus 9.6
836 chromosome 2q35 duplication syndrome 9.6
837 suppressor of tumorigenicity 3 9.6
838 abetalipoproteinemia 9.6
839 joubert syndrome 1 9.6
840 hyperprolinemia, type i 9.6
841 nijmegen breakage syndrome 9.6
842 moyamoya disease 1 9.6
843 myasthenia gravis 9.6
844 mycosis fungoides 9.6
845 nephronophthisis 1 9.6
846 periodontitis, chronic 9.6
847 scott syndrome 9.6
848 reticulum cell sarcoma 9.6
849 retinitis pigmentosa 9.6
850 short stature-obesity syndrome 9.6
851 canavan disease 9.6
852 autism x-linked 2 9.6
853 tn polyagglutination syndrome 9.6
854 arts syndrome 9.6
855 lowe oculocerebrorenal syndrome 9.6
856 androgen insensitivity, partial 9.6
857 aging 9.6
858 kearns-sayre syndrome 9.6
859 frontotemporal dementia 9.6
860 pituitary adenoma, prolactin-secreting 9.6
861 dermatitis herpetiformis, familial 9.6
862 leukoregulin 9.6
863 homocysteinemia 9.6
864 megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1 9.6
865 sickle cell anemia 9.6
866 aceruloplasminemia 9.6
867 maturity-onset diabetes of the young 9.6
868 acute hemorrhagic leukoencephalitis 9.6
869 myopathy, distal, with anterior tibial onset 9.6
870 lissencephaly 1 9.6
871 phobia, specific 9.6
872 major depressive disorder 9.6
873 lung cancer susceptibility 1 9.6
874 mevalonic aciduria 9.6
875 thrombocytopenia 4 9.6
876 major affective disorder 8 9.6
877 major affective disorder 9 9.6
878 encephalocraniocutaneous lipomatosis 9.6
879 tuberous sclerosis 2 9.6
880 birbeck granule deficiency 9.6
881 retinitis pigmentosa 58 9.6
882 beaulieu-boycott-innes syndrome 9.6
883 cyanosis, transient neonatal 9.6
884 multiple enchondromatosis, maffucci type 9.6
885 human herpesvirus 8 9.6
886 peroxisome biogenesis disorder 10a 9.6
887 diarrhea 9 9.6
888 chronic ulcer of skin 9.6
889 angiosarcoma 9.6
890 bacterial sepsis 9.6
891 chikungunya 9.6
892 hemophagocytic lymphohistiocytosis 9.6
893 lissencephaly 9.6
894 fetal alcohol syndrome 9.6
895 alcohol-related birth defect 9.6
896 autosomal recessive disease 9.6
897 secondary progressive multiple sclerosis 9.6
898 atrioventricular block 9.6
899 sleep apnea 9.6
900 follicular lymphoma 9.6
901 adrenal cortical adenoma 9.6
902 cutaneous t cell lymphoma 9.6
903 anosognosia 9.6
904 colitis 9.6
905 ptosis 9.6
906 zika fever 9.6
907 salmonellosis 9.6
908 early-onset parkinson's disease 9.6
909 bone resorption disease 9.6
910 lymphoblastic lymphoma 9.6
911 polycystic kidney disease 9.6
912 hyperprolinemia 9.6
913 distal muscular dystrophy with anterior tibial onset 9.6
914 sleeping sickness 9.6
915 neuroretinitis 9.6
916 pleomorphic lipoma 9.6
917 viral meningitis 9.6
918 eosinophilic meningitis 9.6
919 meningoencephalitis 9.6
920 leukodystrophy 9.6
921 mastitis 9.6
922 methemoglobinemia 9.6
923 hand, foot and mouth disease 9.6
924 strongyloidiasis 9.6
925 megacolon 9.6
926 corneal neovascularization 9.6
927 epidural abscess 9.6
928 iron deficiency anemia 9.6
929 esophagitis 9.6
930 conn's syndrome 9.6
931 inflammatory spondylopathy 9.6
932 blastomycosis 9.6
933 migraine without aura 9.6
934 dementia 9.6
935 esophageal candidiasis 9.6
936 neurosarcoidosis 9.6
937 acute closed-angle glaucoma 9.6
938 sick sinus syndrome 9.6
939 amenorrhea 9.6
940 schistosomiasis 9.6
941 phaeohyphomycosis 9.6
942 autosomal dominant cerebellar ataxia 9.6
943 lymphangioma 9.6
944 candidiasis 9.6
945 normal pressure hydrocephalus 9.6
946 mental depression 9.6
947 histoplasmosis 9.6
948 pancreatic endocrine carcinoma 9.6
949 islet cell tumor 9.6
950 neuroendocrine carcinoma 9.6
951 giant cell tumor 9.6
952 placental choriocarcinoma 9.6
953 gestational choriocarcinoma 9.6
954 drug-induced hepatitis 9.6
955 spondylosis 9.6
956 craniosynostosis 9.6
957 arteriosclerosis 9.6
958 iron metabolism disease 9.6
959 kluver-bucy syndrome 9.6
960 mesenchymoma 9.6
961 irritant dermatitis 9.6
962 contact dermatitis 9.6
963 acute interstitial pneumonia 9.6
964 glucosephosphate dehydrogenase deficiency 9.6
965 pulmonary tuberculosis 9.6
966 cystic lymphangioma 9.6
967 gingivitis 9.6
968 cerebellopontine angle tumor 9.6
969 embryonal carcinoma 9.6
970 bipolar disorder 9.6
971 mammary paget's disease 9.6
972 plague 9.6
973 cellulitis 9.6
974 lateral medullary syndrome 9.6
975 middle cerebral artery infarction 9.6
976 retinitis 9.6
977 angiolipoma 9.6
978 skin disease 9.6
979 cranial nerve palsy 9.6
980 medullomyoblastoma 9.6
981 gastritis 9.6
982 mouth disease 9.6
983 agnosia 9.6
984 mutism 9.6
985 mucoepidermoid carcinoma 9.6
986 nominal aphasia 9.6
987 maxillary cancer 9.6
988 pituitary carcinoma 9.6
989 prosopagnosia 9.6
990 pineal parenchymal tumor of intermediate differentiation 9.6
991 central nervous system vasculitis 9.6
992 functioning pituitary adenoma 9.6
993 testicular germ cell cancer 9.6
994 malignant mesenchymoma 9.6
995 conjunctivitis 9.6
996 growth hormone secreting pituitary adenoma 9.6
997 viral encephalitis 9.6
998 clivus meningioma 9.6
999 plasma cell neoplasm 9.6
1000 spondylitis 9.6
1001 hepatoblastoma 9.6
1002 fibrous meningioma 9.6
1003 pseudosarcomatous fibromatosis 9.6
1004 diverticulitis 9.6
1005 intracranial chondrosarcoma 9.6
1006 frontal convexity meningioma 9.6
1007 olfactory groove meningioma 9.6
1008 carotid artery occlusion 9.6
1009 periodontitis 9.6
1010 appendicitis 9.6
1011 ileus 9.6
1012 choline deficiency disease 9.6
1013 dermatitis herpetiformis 9.6
1014 bullous pemphigoid 9.6
1015 chickenpox 9.6
1016 vascular dementia 9.6
1017 tonsil cancer 9.6
1018 amebiasis 9.6
1019 speech disorder 9.6
1020 mechanical strabismus 9.6
1021 lymphangitis 9.6
1022 fatty liver disease 9.6
1023 krukenberg carcinoma 9.6
1024 fasciitis 9.6
1025 keloid disorder 9.6
1026 myotonic dystrophy 9.6
1027 parkin type of early-onset parkinson disease 9.6
1028 aids dementia complex 9.6
1029 autoimmune encephalitis 9.6
1030 cerebellar degeneration 9.6
1031 congenital extrahepatic portosystemic shunt 9.6
1032 dentinogenesis imperfecta type 2 9.6
1033 desmoplastic infantile astrocytoma 9.6
1034 encephalocele 9.6
1035 epidermoid brain cyst 9.6
1036 hemangioendothelioma 9.6
1037 human t-cell leukemia virus type 1 9.6
1038 meningoencephalocele 9.6
1039 nephrogenic systemic fibrosis 9.6
1040 ovarian epithelial cancer 9.6
1041 pituitary stalk interruption syndrome 9.6
1042 plasmablastic lymphoma 9.6
1043 punctate porokeratosis 9.6
1044 radiation induced cancer 9.6
1045 ring chromosome 7 9.6
1046 splenomegaly 9.6
1047 tetraploidy 9.6
1048 aids - neurological complications 9.6
1049 brain and spinal tumors 9.6
1050 brain injury 9.6
1051 chronic pain 9.6
1052 spinal cord injury 9.6
1053 cerebrofacial arteriovenous metameric syndrome 9.6
1054 central nervous system embryonal tumor 9.6
1055 partial duplication of chromosome 7 9.6
1056 rare lymphatic malformation 9.6
1057 acute sensory ataxic neuropathy 9.6
1058 ciliopathy 9.6
1059 ring chromosome 9.6
1060 gonadal germ cell tumor 9.6
1061 polymerase proofreading-related adenomatous polyposis 9.6
1062 statin toxicity 9.6
1063 non-functioning pituitary adenoma 9.6
1064 brain inflammatory disease 9.6

Graphical network of the top 20 diseases related to Glioblastoma Multiforme:



Diseases related to Glioblastoma Multiforme

Symptoms & Phenotypes for Glioblastoma Multiforme

Human phenotypes related to Glioblastoma Multiforme:

58 (showing 15, show less)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 58 Occasional (29-5%)
2 muscle weakness 58 Frequent (79-30%)
3 fatigue 58 Frequent (79-30%)
4 memory impairment 58 Occasional (29-5%)
5 abnormality of the cerebral white matter 58 Frequent (79-30%)
6 visual loss 58 Frequent (79-30%)
7 paralysis 58 Frequent (79-30%)
8 headache 58 Frequent (79-30%)
9 cerebral edema 58 Frequent (79-30%)
10 language impairment 58 Frequent (79-30%)
11 abnormality of nervous system physiology 58 Frequent (79-30%)
12 abnormal cell morphology 58 Very frequent (99-80%)
13 abnormal corpus callosum morphology 58 Frequent (79-30%)
14 mood changes 58 Frequent (79-30%)
15 glioblastoma 58 Obligate (100%)

UMLS symptoms related to Glioblastoma Multiforme:


seizures, headache

GenomeRNAi Phenotypes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

26 (showing 16, show less)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.56 EGFR HRAS MTOR PIK3CA BRAF
2 Decreased viability GR00221-A-1 10.56 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
3 Decreased viability GR00221-A-2 10.56 FGFR1 HRAS PIK3CA
4 Decreased viability GR00221-A-3 10.56 HRAS NRAS
5 Decreased viability GR00221-A-4 10.56 EGFR MTOR PIK3CA BRAF
6 Decreased viability GR00301-A 10.56 BRAF
7 Decreased viability GR00342-S-1 10.56 MTOR
8 Decreased viability GR00342-S-2 10.56 MTOR
9 Decreased viability GR00381-A-1 10.56 BRAF
10 Decreased viability GR00402-S-2 10.56 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
11 Decreased cell migration GR00055-A-1 9.72 BRAF EGFR HRAS MTOR PIK3CA
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 EGFR HRAS MTOR NRAS PTEN
13 Decreased viability with paclitaxel GR00179-A-1 9.35 EGFR MTOR
14 Decreased viability with paclitaxel GR00179-A-2 9.35 MTOR
15 Decreased viability with paclitaxel GR00179-A-3 9.35 EGFR MTOR
16 Increased cell migration GR00055-A-3 9.02 BRAF EGFR HRAS MTOR PIK3CA

MGI Mouse Phenotypes related to Glioblastoma Multiforme:

45 (showing 11, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.19 BCOR BRAF EGFR FGFR1 HRAS MTOR
2 immune system MP:0005387 10.15 BCOR BRAF EGFR FGFR1 IDH1 MSH2
3 hematopoietic system MP:0005397 10.14 BCOR BRAF EGFR FGFR1 IDH1 MSH2
4 digestive/alimentary MP:0005381 10.13 BRAF EGFR FGFR1 HRAS MSH2 NRAS
5 endocrine/exocrine gland MP:0005379 10.13 BRAF EGFR FGFR1 HRAS MTOR NRAS
6 embryo MP:0005380 10.11 BCOR BRAF EGFR FGFR1 MTOR NRAS
7 integument MP:0010771 9.97 BRAF EGFR FGFR1 HRAS MSH2 NRAS
8 neoplasm MP:0002006 9.91 BRAF EGFR HRAS MSH2 NRAS PIK3CA
9 no phenotypic analysis MP:0003012 9.7 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
10 pigmentation MP:0001186 9.35 BRAF EGFR NRAS PTEN TP53
11 skeleton MP:0005390 9.32 BRAF EGFR FGFR1 HRAS IDH1 MTOR

Drugs & Therapeutics for Glioblastoma Multiforme

Drugs for Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 612, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
6
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
7
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Trioxsalen Approved Phase 3 3902-71-4 5585
10
Donepezil Approved Phase 3 120014-06-4 3152
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Streptozocin Approved, Investigational Phase 2, Phase 3 18883-66-4 29327
13
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
14
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
15
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
16
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
17
Etoposide Approved Phase 3 33419-42-0 36462
18
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
19
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
20
Gemcitabine Approved Phase 3 95058-81-4 60750
21
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
22
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
23
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
24
Bevacizumab Approved, Investigational Phase 3 216974-75-3
25
Iodine Approved, Investigational Phase 3 7553-56-2 807
26
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
27
Povidone Approved Phase 3 9003-39-8
28
Povidone-iodine Approved Phase 3 25655-41-8
29
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
30
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652